Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Examine The Efficacy And Safety Of ZX008 In Subjects With CDKL5 Deficiency Disorder Followed By An Open-Label Extension

NCT05064878 is registered in ClinicalTrials.gov with Zogenix, Inc. as lead sponsor.

NCT NCT05064878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05064878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Examine The Efficacy And Safety Of ZX008 In Subjects With CDKL5 Deficiency Disorder Followed By An Open-Label Extension
Lead sponsor
Zogenix, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 8, 2022
Completion date
November 8, 2027
Enrollment
87 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

cdkl5 deficiency disorder, epileptic spasm, generalized tonic clonic seizure, refractory seizures